Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. - Wikidata - awgldk - TriplyDB

Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.

Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.

http://www.wikidata.org/entity/Q38826522

about

Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials.The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study Evolution of lymphoma staging and response evaluation: current limitations and future directions.Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments.Clinical Trials in the Genomic Era.Report of the 6th International Workshop on PET in lymphoma.FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.Targeted PET imaging strategy to differentiate malignant from inflamed lymph nodes in diffuse large B-cell lymphoma.Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.Minimal Residual Disease Assessment in Lymphoma: Methods and Applications.Hodgkin lymphoma: A review and update on recent progress.18F-FDG PET/CT in Lymphoma: Has Imaging-Directed Personalized Medicine Become a Reality?Therapy monitoring with PET in cancer patients: achievements, opportunities and challenges ahead for the PET community.Whole body magnetic resonance in indolent lymphomas under watchful waiting: The time is now.Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors.Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review.Interim FDG-PET in lymphoma, a questionable practice in hematology.Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma.Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.18F-FDG PET/MR imaging of lymphoma nodal target lesions: Comparison of PET standardized uptake value (SUV) with MR apparent diffusion coefficient (ADC).Targeting Immune System Alterations in Hodgkin Lymphoma.[18F]FDG-PET/CT in Hodgkin Lymphoma: Current Usefulness and Perspectives.The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma.Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial Application of Quantitative Indexes of FDG PET to Treatment Response Evaluation in Indolent Lymphoma

P2860

Q33820910-4FD6592F-D5F3-42E0-A852-87FDEEB54929 Q33849498-7887182A-1BB5-42E7-B341-18BEC6390EA0 Q38671671-65261D02-3510-4716-B68B-C2C9815F5B0A Q38737416-4F7284BC-6387-4297-B380-EE429FA6A817 Q38905607-6B015766-0FE9-4A3A-ADEA-A4E5BEAA2065 Q38926460-203E35E1-B3BD-4979-AEC7-5BE5B002A368 Q39259769-A88BFD3E-3E0E-4004-BF5B-3C89C004F320 Q41269380-55724144-D8CA-4483-A4B3-5A5C6D81F62C Q47563022-F1AFD806-6231-4F75-8F10-908FCBF2EB55 Q47568589-7DDE0AEA-5C7D-475F-B64C-0089BFAAE2F4 Q47807176-07A754FC-19AC-4CC7-BF7D-B27E4F8E07CB Q47808320-7F81B667-79B4-402D-B988-1625CCC701BD Q48105701-FF80A843-00F4-45E1-8706-BCA2C855D2A0 Q48212826-B618A7CE-B913-4BBA-975F-CB38027B5BE1 Q48227716-CB8C39C3-0743-424A-BF02-C7439354DA12 Q48265648-3759E60F-C714-4B39-8A79-FB51814EDA8F Q48316502-929AD792-D561-4751-ADC0-1CA61DC6100F Q48618984-C7B4B6F1-FCD1-4731-B569-71DAF62A6B96 Q48669191-FD36FB90-C8A5-4D16-B183-BA1D2E74D59C Q48689919-015313F6-6B3F-41C4-B03F-F98408B52402 Q50271165-6FC10CDF-F00F-4E0A-B51F-993DAFC9B501 Q52929230-54455508-CB59-42F5-9819-58FB9422FC86 Q53123844-BD590642-F1FF-4B73-8A2B-692210FD9312 Q55220794-B2548993-6E7F-4B4C-950B-80B1883E3B06 Q55495617-0EA609E2-0EE4-4899-8AF2-C1538EFA98B1 Q56383260-C58FA6CF-1B38-46F0-9DF9-E53A2E890EC7 Q57820488-3597B2D8-66EF-4DF3-89F0-26704D8DA697

P2860

Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.

http://www.wikidata.org/entity/Q38826522

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Refinement of the Lugano Class ...... a of immunomodulatory therapy.

@en

type

label

Refinement of the Lugano Class ...... a of immunomodulatory therapy.

@en

prefLabel

Refinement of the Lugano Class ...... a of immunomodulatory therapy.

@en

P1433

Q38826522-A5AF23C5-1335-439F-95EB-20608C8514E0

P1476

Q38826522-7571E643-DB20-4B9F-8E9D-EB25740F66BA

P2093

Q38826522-185F9A89-9566-4813-ABAA-AD7490DB1590

Q38826522-18B62F04-8A37-4C59-B7AF-18CC6F3C5A09

Q38826522-1BD6A2BB-7B52-4301-9433-587AABF06838

Q38826522-33208FE0-F54A-4272-83F3-95FB78E49667

Q38826522-380B1DAD-D992-4C6C-822F-5C740CDBF74B

Q38826522-3D5F6CD0-0FA7-401F-8095-B69429CA55DB

Q38826522-89004033-B74C-4857-8DF8-1D699DBB6A76

Q38826522-B0425521-EA6A-4E97-8950-8BDB24F9809B

P304

Q38826522-1766E78C-F647-4B6E-AA34-C4C1999D70BD

P31

Q38826522-4E01149A-CE0D-42A8-A86F-C80D4F61B487

P356

Q38826522-65B5C32B-5A2B-40DF-8898-0379851A2C93

P407

Q38826522-F7165D42-5A9A-4E02-8C15-732D6551B41D

P433

Q38826522-381C3BBD-243E-4463-9F97-C49A6CC637D2

P478

Q38826522-21FBEC4A-FEAB-4527-BA43-8F241741D219

P50

Q38826522-4084B8A2-BA99-44C7-88E7-28B59AC69526

P577

Q38826522-5B1C8B8C-71A1-4478-A592-2DEFC5223E15

P698

Q38826522-0EF1C6BF-C3FE-4035-9AE7-B4CAED5D618A

P356

BLOOD-2016-05-718528

P1433

P1476

Refinement of the Lugano Class ...... ra of immunomodulatory therapy

@en

P2093

Axel Hoos

http://www.w3.org/2001/XMLSchema#string

Bruce D Cheson

http://www.w3.org/2001/XMLSchema#string

Heather A Jacene

http://www.w3.org/2001/XMLSchema#string

Larry Schwartz

http://www.w3.org/2001/XMLSchema#string

Leo I Gordon

http://www.w3.org/2001/XMLSchema#string

Philippe Armand

http://www.w3.org/2001/XMLSchema#string

Ranjana Advani

http://www.w3.org/2001/XMLSchema#string

Stephen Ansell

http://www.w3.org/2001/XMLSchema#string

P304

2489-2496

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2016-05-718528

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

128

http://www.w3.org/2001/XMLSchema#string

P50

Sally Barrington

P577

2016-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27574190

http://www.w3.org/2001/XMLSchema#string